Structure of Recombinant Human CPP32 in Complex with the Tetrapeptide Acetyl-Asp-Val-Ala-Asp Fluoromethyl Ketone*

(Received for publication, September 18, 1996, and in revised form, December 18, 1996)

Peer R. E. Mittl Dagger §, Stefania Di Marco Dagger §, Joseph F. Krebs , Xu Bai , Donald S. Karanewsky , John P. Priestle Dagger , Kevin J. Tomaselli and Markus G. Grütter Dagger par

From Dagger  Core Drug Discovery Technologies, Ciba-Geigy AG, CH-4002 Basel, Switzerland and  IDUN Pharmaceuticals, Inc., La Jolla, California 92037

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

The cysteine protease CPP32 has been expressed in a soluble form in Escherichia coli and purified to >95% purity. The three-dimensional structure of human CPP32 in complex with the irreversible tetrapeptide inhibitor acetyl-Asp-Val-Ala-Asp fluoromethyl ketone was determined by x-ray crystallography at a resolution of 2.3 Å. The asymmetric unit contains a (p17/p12)2 tetramer, in agreement with the tetrameric structure of the protein in solution as determined by dynamic light scattering and size exclusion chromatography. The overall topology of CPP32 is very similar to that of interleukin-1beta -converting enzyme (ICE); however, differences exist at the N terminus of the p17 subunit, where the first helix found in ICE is missing in CPP32. A deletion/insertion pattern is responsible for the striking differences observed in the loops around the active site. In addition, the P1 carbonyl of the ketone inhibitor is pointing into the oxyanion hole and forms a hydrogen bond with the peptidic nitrogen of Gly-122, resulting in a different state compared with the tetrahedral intermediate observed in the structure of ICE and CPP32 in complex with an aldehyde inhibitor. The topology of the interface formed by the two p17/p12 heterodimers of CPP32 is different from that of ICE. This results in different orientations of CPP32 heterodimers compared with ICE heterodimers, which could affect substrate recognition. This structural information will be invaluable for the design of small synthetic inhibitors of CPP32 as well as for the design of CPP32 mutants.


INTRODUCTION

Genetic and biochemical studies have established the importance of the CED3/ICE1 proteases in programmed cell death or apoptosis (1-4). Of the known mammalian CED3/ICE proteases, CPP32 is the most similar in sequence homology and substrate specificity to the CED3 protease (2, 5), whose function is required for programmed cell death in the developing Caenorhabditis elegans hermaphrodite (6). CED3/ICE proteases are synthesized as single chain proenzymes that are cleaved proteolytically to produce catalytically active cysteine proteases with specificity for cleavage at Asp-X peptide bonds (7-9). In several apoptotic model systems, CPP32 is rapidly processed from its p32 proenzyme form to a p17/p12 catalytically active form (10-12). Cleavage and activation of CPP32 are thought to be mediated by CED3/ICE proteases (12, 13), possibly including active CPP32 itself, MCH2, and/or MCH4 (14, 15). Several proteins that regulate cellular homeostasis and function, including poly(ADP-ribose) polymerase, the 70-kDa subunit of the U1 small ribonucleoprotein, the catalytic subunit of DNA-dependent protein kinase, and the Huntington's disease gene product (huntingtin), are thought to be target substrates for activated CPP32 (8, 16-18). Thus, activation of CED3/ICE proteases, including CPP32, within pre-apoptotic cells is thought to lead to the proteolytic inactivation of proteins that are necessary for cell viability. In support of this hypothesis, CED3/ICE protease inhibitors have been shown to block cell death in several model systems (3, 19, 20).

The CED3/ICE family can be divided into two subfamilies on structural grounds, the ICE subfamily and the CED3 subfamily, with the prototypical human representatives being ICE and CPP32, respectively. ICE and CPP32 differ in both substrate recognition and inhibitor binding. Regarding substrate cleavage, ICE displays a preference for hydrophobic residues in the P4 position, while known substrates of CPP32 contain aspartic acid at P4. Thus, ICE efficiently cleaves pro-interleukin-1beta at a (P4)Tyr-Val-His-Asp(P1) sequence to generate mature interleukin-1beta , while CPP32 does not (7, 8). CPP32 catalyzes the cleavage of several protein substrates, including poly(ADP-ribose) polymerase, at (P4)Asp-X-X-Asp(P1) motifs much more efficiently than does ICE (8, 21). Differences in the active sites of these two proteases are also reflected in their abilities to bind inhibitors. For example, the cowpox virus serpin CrmA inhibits ICE 5 orders of magnitude more potently than it does CPP32 (8). Similarly, the tetrapeptide aldehyde acetyl-Tyr-Val-Ala-Asp-aldehyde (Ac-YVAD-aldehyde), corresponding to the ICE cleavage site in pro-interleukin-1beta , inhibits ICE 5 orders of magnitude better than it does CPP32 (8). The tetrapeptide acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-aldehyde), derived from the CPP32 cleavage site in poly(ADP-ribose) polymerase (8, 22), is a potent inhibitor of both CPP32 and ICE, with only a 50-fold selectivity for CPP32 (23). To understand the structural basis for the similarities and differences in inhibitor recognition by CPP32 and ICE, we have solved the x-ray structure at 2.3 Å of recombinant CPP32 complexed to an irreversible tetrapeptide inhibitor, acetyl-Asp-Val-Ala-Asp fluoromethyl ketone (Ac-DVAD-fmk), and compared it with two previously published ICE structures (24, 25) and a recently published 2.5-Å structure of CPP32 (23).


EXPERIMENTAL PROCEDURES

Materials

Ac-YVAD-aldehyde and Ac-DEVD-aldehyde were purchased from Bachem Bioscience Products (King of Prussia, PA). Acetyl-Asp-Glu-Val-Asp aminomethylcoumarin (Ac-DEVD-amc) was synthesized as described (12).

CPP32 Production

The cloned full-length CPP32 gene (14) was inserted into the BamHI/XhoI sites of the pET21b plasmid (Novagen, Madison, WI), which fused a His6 tag to the CPP32 C terminus. Escherichia coli BL21(DE3) cells containing this plasmid were grown to a density of A600 nm = 1.9 at 37 °C in 3 liters of induction medium (20 g/liter Tryptone, 10 g/liter yeast extract, 5 g/liter NaCl, 0.5 × M9 salts, 0.4% glucose, 1 mM MgCl2, 0.1 mM CaCl2, and 0.1 mg/ml ampicillin, pH 7.4). Isopropyl-1-thio-beta -D-galactopyranoside (1 mM) was added, and the culture was shaken at 25 °C for 3 h. Cells were pelleted and resuspended in 100 ml of binding buffer (20 mM Tris-HCl, 5 mM imidazole, and 500 mM NaCl, pH 8.0) containing 0.1 mg/ml lysozyme and 0.1% Triton X-100. After incubation on ice for 40 min, the cells were flash-frozen and stored at -80 °C. After centrifugation, lysate supernatant was loaded onto a 12-ml Ni2+-charged HisBind metal affinity column (Novagen) equilibrated with binding buffer. The purified CPP32 protein was eluted from the column using a linear 60-1000 mM imidazole gradient (total volume of 100 ml). Fractions containing CPP32 activity were mixed with an equal volume of 0.1 M HEPES and 0.1 M dithiothreitol, pH 8.9, and then 2 mol eq of Ac-DVAD-fmk were added to prevent autoproteolysis. The inhibited enzyme was concentrated by ultrafiltration and buffer-exchanged into 25 mM HEPES, 50 mM NaCl, 1 mM EDTA, 2 mM dithiothreitol, and 0.02% NaN3, pH 7.5. All procedures were done at 4 °C.

Inhibitor Synthesis

Ac-DVAD-fmk was prepared via a Swern oxidation of Ac-Asp-(OBut)-Val-Ala-NHCH(CH2CO2But)CH(OH)CH2F with oxalyl chloride/triethylamine in dimethyl sulfoxide/CH2Cl2, followed by deprotection with 50% trifluoroacetic acid in CH2Cl2. The requisite alcohol was prepared by catalytic hydrogenation of benzyloxycarbonyl-Val-Ala-NHCH(CH2CO2But)CH(OH)CH2F over 10% palladium on carbon in methanol, followed by coupling to Ac-Asp-(OBut)-OH with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/1-hydroxybenztriazol in CH2Cl2/dimethylformamide. Benzyloxycarbonyl-Val-Ala-NHCH(CH2CO2But)CH(OH)CH2F, in turn, was prepared by coupling benzyloxycarbonyl-Val-Ala-OH to H2NCH(CH2CO2But)CH(OH)CH2F (26) with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/1-hydroxybenztriazol.

Analytical Methods

Protein concentration was determined with the Bio-Rad protein assay, with bovine serum albumin as standard. Automated Edman degradation for N-terminal sequence analysis was performed using a gas-phase sequencer (Model 477A, Applied Biosystems Inc.). Phenylthiohydantoin-derivatives were analyzed by gradient liquid chromatography on a phenylthiohydantoin-derivative analyzer (Model 120A, Applied Biosystems Inc.). Matrix-assisted laser-desorption ionization/time of flight mass spectrometry was performed using sinapinic acid as matrix (27). Reversed-phase high pressure liquid chromatography was performed using a C18 column (0.46 × 11 cm, 5 µm) equilibrated at room temperature with 0.1% trifluoroacetic acid in water. The column was eluted at 1 ml/min with a 15-min linear gradient (16-48% acetonitrile in 0.07% trifluoroacetic acid), and the eluate was monitored at 214 nm. SDS-polyacrylamide gel electrophoresis was performed on cast gels (10-20% acrylamide gradient gel) in a Tris/Tricine system (28). Gels were stained with Coomassie Blue G-250 (29). Gel filtration analysis of the CPP32-inhibitor complex was performed at 4 °C using a 1.6 × 70-cm Sephadex G-75 column (Pharmacia Biotech Inc.) equilibrated with 25 mM HEPES, 50 mM NaCl, 1 mM EDTA, 2 mM dithiothreitol, and 0.02% NaN3, pH 7.5. The protein was chromatographed in the same buffer at a flow rate of 0.2 mg/ml. The elution volume was compared against a standard curve of the column calibrated with molecular weight markers (Bio-Rad).

Enzymatic Assay

The enzymatic activity of CPP32 was determined from the initial rate of Ac-DEVD-amc substrate hydrolysis in 25 mM HEPES, 1 mM EDTA, 2 mM dithiothreitol, 0.1% CHAPS, and 10% sucrose, pH 7.5. Aminomethylcoumarin product formation was detected by the increase in sample fluorescence (lambda ex = 360 nm, lambda em = 460 nm) for 1 h at room temperature using a Cytofluor II fluorescent plate reader (PerSeptive Biosystems, Framingham, MA). For kinetic and inhibitory measurements, the final substrate concentration range was 1-200 µM, while the enzyme concentration was 32 pM. For inhibition constant (Ki) determinations, the enzyme and inhibitor were preincubated for 30 min at room temperature prior to the addition of the substrate.

Dynamic Light Scattering

Light scattering was performed with a Dynapro-801 molecular sizing instrument (Protein Solutions, Inc., Charlottesville, VA). Data analyses were performed with Protein Solutions Auto Pro Data analysis software. The purified protein was injected through a 0.02-µm syringe filter at room temperature into the Dynapro-801 detector. The sample was measured at a protein concentration of 2.6 mg/ml.

Crystallization and Data Collection

The hanging and sitting drop methods of vapor diffusion at 4 °C were used (30). CPP32 protein (2-4 µl) inhibited with Ac-DVAD-fmk (at a protein concentration of 5.3 mg/ml) was mixed with 2-4 µl of buffer consisting of 5% (w/v) polyethylene glycol 8000, 50 mM magnesium acetate, 90 mM sodium cacodylate, and 80 mM sodium sulfate, pH 6.3-6.5. Within ~1 week at 4 °C, crystals grew to a size of 0.3 × 0.2 × 0.5 mm3. X-ray diffraction data were collected at 4 °C from a single crystal using a 30-cm MAR Research imaging plate detector system. Graphite-monochromated CuKalpha radiation was provided by an Enraf Nonius FR591 rotating anode x-ray generator operated at 45 kV and 90 mA. A preliminary native data set from a small crystal was collected at room temperature using monochromated synchrotron radiation at the Swiss-Norwegian Beam Line, European Synchrotron Radiation Facility (Grenoble, France). Data collection and processing were performed using MAR Research imaging plate software (31-33). Processing statistics for both data sets are given in Table I.

Table I.

Data collection statistics


Data set 1 Data set 2 

Space group P21 P21
Unit cell parameters (Å) a = 50.9, b = 69.1, c = 93.8 a = 50.6, b = 69.4, c = 94.6 
 alpha  = 90°, beta  = 101.2°, gamma  = 90°  alpha  = 90°, beta  = 101.9°, gamma  = 90°
Wavelength (Å) 0.873 1.5418
Temperature (°C) 20 4
Crystal to detector distance (mm) 350 110
Frame size/exposure (°/s) 1.0/180 0.5/600
All data Last shell All data Last shell

Resolution (Å) 30.0 to 2.6 2.80 to 2.60 32.0 to 2.30 2.50 to 2.30 
Completeness (%) 94.4 96.7 83.7 78.6
Rsvm (%) 8.1 39.6 6.9 23.7
>=  3sigma (%) 70.6 41.7 62.7 35.9
Unique reflections 18,690 3780 24,128 5092
Multiplicity 2.7 2.7 1.6 1.6

Structure Solution and Refinement

The synchrotron data set was used to solve the structure by molecular replacement with the program AMoRe (34). As a template, a p17/p12 heterodimer of a previously constructed homology model, created on the basis of the ICE structure (25), was used. Two peaks were found in the cross-rotation function for the rotation angles alpha  = 76.11°, beta  = 149.64°, gamma  = 56.28° (peak height = 5.8sigma , 8.0 to 3.0-Å resolution, and 25-Å Patterson radius) and alpha  = 323.10°, beta  = 52.62°, gamma  = 186.75° (peak height = 5.5sigma ). The two-dimensional translation function, calculated with the search model rotated according to the first set of angles in the resolution range 8.0 to 3.0 Å, yielded a solution for the translation a = 0.4306, b = 0.0000, and c = 0.3672 (correlation coefficient (r) = 29.8%, R-factor = 53.5%).2 For the calculation of the second translation function, the first molecule was fixed in its previously determined orientation. This function gave a correlation maximum at a = 0.1734, b = 0.2189, and c = 0.1169 (r = 35.8%, R-factor = 52.1%). The two orientations were improved by rigid-body refinement (R-factor = 51.1%, 8.0- and 3.0-Å resolution). The structure was further refined using the rotating anode data set by alternating rounds of molecular dynamics refinement from 3000 to 300 K (program X-PLOR) (35) and manual interventions on a graphic terminal (program O) (36). The R-factor converged at 18.8% for all data between 8.0- and 2.3-Å resolution (free R-factor = 28.4%). During the refinement, 346 water molecules were included in the structure. The root mean square deviations for bond lengths and angles were 0.013 Å and 1.71°, respectively. The structure contains two copies each of the p17 and p12 subunits and the inhibitor. The first dimer, (p17/p12/one inhibitor)-molecule, is numbered 35-173, 185-277, and 989-993, respectively. The second dimer, (p17/p12/one inhibitor)-molecule, is numbered 1035-1173, 1185-1277, and 1989-1993, respectively. Not all residues could be assigned due to a too weak electron density. In the p17 subunit, 6 residues could not be located at the N terminus and 2 residues at the C terminus. In the p12 subunit, 9 N-terminal residues and 8 C-terminal residues (Leu-Glu-His6) could not be fitted. The root mean square deviation of 0.35 Å for the C-alpha distance, when comparing the two p17/p12 heterodimers, is in the range of the coordinate error. Therefore, they can be considered to be identical. Due to significantly higher temperature factors, the electron density for the second p17/p12 dimer (residues 1035-1993) is worse than for the first dimer (residues 35-993). The average temperature factors for the two p17/p12 heterodimers and inhibitor molecules are 25.5 Å2 (residues 35-277), 36.7 Å2 (residues 1035-1277), 24.0 Å2 (residues 989-993), and 33.9 Å2 (residues 1989-1993), respectively. The average temperature factor for discrete water molecules is 49.6 Å2.


RESULTS AND DISCUSSION

Expression of Pro-CPP32 in Bacteria Yields Processed Active Enzyme That Is Indistinguishable from Native Enzyme

Soluble active recombinant CPP32 was produced in E. coli using a T7 expression system. The enzymatic activity present in the induced cell lysate indicated that 46 mg of active CPP32 were produced from a 3-liter culture. The enzyme was readily purified from the lysate using metal chelate affinity chromatography. Although CPP32 was expressed as the 32-kDa proenzyme, purified CPP32 is composed of two subunits in a 1:1 molar ratio with molecular masses of 17 and 12 kDa, which indicates that the proenzyme has been processed to mature enzyme in E. coli (Table II). Like the native enzyme (8), active recombinant CPP32 is generated by cleavage of the proenzyme at Asp-28 and Asp-175, as determined by N-terminal sequencing and matrix-assisted laser-desorption ionization/time of flight mass spectrometry (Table II). Two possible explanations for the CPP32 proenzyme processing are that CPP32 processes itself, or a bacterial protease processes CPP32. We favor the first possibility for two reasons. First, there is some evidence that in vitro translated CPP32 can cleave its own pro-domain after the p17/p12 cleavage is made; and second, pro-CPP32 in the bacterial lysate is converted to p17/p12 during the Ni2+ affinity chromatography step, possibly on the column itself (data not shown). The Km values for Ac-DEVD-amc and the inhibition constants for Ac-DEVD-aldehyde and Ac-YVAD-aldehyde for recombinant CPP32 are nearly identical to the published values for the natural enzyme (Table III).

Table II.

Characterization of recombinant human CPP32


N-terminal sequence analysis (40 steps)
  p17 SGISLDNSYKMD... (residues 29-175)
  p12 SGVDDDMACHKI... (residues 176-277 plus LEHHHHHH)
Molecular mass (MALDI/TOF mass spectrometry)
  p17 With inhibitor Ac-DVAD-fmk: 17,058 Da (calculated, 17,071.4 Da)
  p12 12,952 Da (calculated, 12,959.7 Da)
Purity by RP-HPLC >95%, two peaks in a 1:1 molar ratio
Purity by SDS-PAGE Two bands, 17 and 12 kDa

a MALDI/TOF, matrix-assisted laser-desorption ionization/time of flight; RP-HPLC, reversed-phase high pressure liquid chromatography; PAGE, polyacrylamide gel electrophoresis.

Table III.

Kinetic and inhibitory values for purified CPP32


Natural human CPP32a Recombinant human CPP32

Km Ac-DEVD-amc (µM) 9.7 8.6
Ki Ac-DEVD-aldehyde (nM) 0.2 0.8
Ki Ac-YVAD-aldehyde (µM) >10 12

a Data from Ref. 8.

Processed CPP32 Exists as a Homo-heterodimer in Solution

Purified CPP32 was inactivated with the potent irreversible inhibitor Ac-DVAD-fmk (k3/Ki = 5.5 × 105 M-1 s-1). The quaternary structure of purified inhibited CPP32 was analyzed by gel filtration chromatography and dynamic light scattering. The processed CPP32 protein eluted from the column as a single peak at a position consistent with a molecular mass of 52 kDa (data not shown), which is 1.7 times the predicted molecular mass of the inhibited p17/p12 heterodimer (30 kDa). This result was confirmed by light scattering. Assuming the protein to be globular in nature, molecular size estimation showed recombinant CPP32 to have a hydrodynamic radius of 32.5 Å, with a standard deviation of the spread of particle sizes about the reported average radius of 4.9 Å, corresponding to a monodisperse solution (<15% polydispersity). Software-based conversion of hydrodynamic radius measurements estimated a molecular mass of 52 kDa, confirming that CPP32 exists as a (p17/p12)2 tetramer in solution. Empirical observations suggest that macromolecules that are monodisperse in solution (i.e. are all the same size) crystallize readily, whereas randomly aggregating or polydisperse systems usually do not yield crystals (37). Recombinant CPP32 was readily co-crystallized with the Ac-DVAD-fmk inhibitor.

Topology of CPP32

The structure of CPP32 contains two copies each of the p17 and p12 chains that contain residues 35-173 and 185-277, respectively. The four polypeptide chains associate to form a (p17/p12)2 tetramer, which folds into one compact structure with overall dimensions of ~50 × 60 × 30 Å3. The p17 and p12 subunits interact extensively with each other, and the structure is better described as a homodimer of p17/p12 heterodimers. A further subdivision of the p17/p12 dimer into separate domains is impossible since it appears as a single folding unit (Fig. 1). The core of the enzyme is formed by a central 12-stranded beta -sheet. Each p17/p12 dimer donates six strands. The first five strands are all parallel. Only the innermost strand f is directed antiparallel to strands e and f# (# denotes parts from the non-crystallographic symmetry-related dimer). The central beta -sheet shows a left-handed 50° twist and is surrounded by 10 alpha -helices. Looking down the 2-fold symmetry that relates the two p17/p12 dimers, helices 1, 4, 5, 1#, 4#, and 5# are located below the central beta -sheet, and helices 2, 3, 2#, and 3# are located above. Helices 1-3 and strands a-d belong to the p17 subunit, and helices 4 and 5 and strands e and f to the p12 subunit. The borders of the secondary structural elements are given in Fig. 2.


Fig. 1. Ribbon diagram of a p17/p12 dimer. The p17 and p12 subunits are colored in light and dark gray, respectively. The inhibitor Ac-DVAD-fmk is shown as a ball-and-stick model. beta -Sheets and alpha -helices are labeled similarly as described in the legend to Fig. 2. The figure was generated with MOLSCRIPT (44).
[View Larger Version of this Image (56K GIF file)]



Fig. 2. Topology diagram of the CPP32 (p17/p12)2 tetramer. Squares represent beta -strands, and circles represent alpha -helices. Concentric circles are directed into the paper plane, and simple circles are coming out of the paper plane. Lower-case letters represent beta -strands; the helices are numbered. The borders of the secondary structure are specified in the left heterodimer. The 2-fold symmetry is indicated. The beta -sheet is twisted 50° counterclockwise. Thick arrows represent the inhibitors. N12, C12, N17, and C17 refer to the N and C termini of p12 and p17, respectively. Since the heterodimer on the right-hand site represents the 2-fold symmetry mate, all labels have number signs.
[View Larger Version of this Image (21K GIF file)]


The C terminus of p17 and the N terminus of the non-crystallographic symmetry-related p12 subunit are in close contact (Fig. 2). Since the two dimers are related by a 2-fold axis, the C terminus of p17 and the N terminus of p12 from the same p17/p12 dimer are 50 Å away from each other. If both subunits in one p17/p12 dimer would come from the same polypeptide chain, larger structural rearrangements during the maturation of CPP32 would have to take place. It is therefore quite unlikely that these subunits were generated by cleaving a single polypeptide chain in the proenzyme, as suggested by the recently published CPP32 structure (23) and by the two ICE structures (24, 25). The close proximity of the p12 N terminus and the p17 C terminus coming from different dimers (Fig. 2) implies a different folding pathway. It seems to be more likely that two different proenzymes associate to form a protetramer. The maturation of the protease involves the subsequent cleavage of the protetramer by CPP32 itself (38) or by other proteases at multiple sites, like cytotoxic T cell serine protease granzyme B (39) or other ICE-like proteases, in an ordered signal transduction cascade (15, 16).

The overall topology of CPP32 is very similar to that of ICE (24, 25). In fact, the two structures can be superimposed with a root mean square deviation of 1.3 Å for C-alpha atoms (residues 35-40, 45-57, 60-107, 108-131, 132-170, 188-245, 258-266, and 267-276 from CPP32 and the corresponding residues from ICE). Striking differences exist at the N terminus of p17, where the first alpha -helix found in ICE is missing in CPP32 (Fig. 3). These residues present no significant sequence homology to ICE. Although purified CPP32 contains Ser-29-Asn-35, they are not defined in the electron density, indicating that they are disordered. N-terminal sequencing of redissolved crystals confirmed the presence of these residues. Striking differences are also observed for the loops around the active site and at the interface between the two p17/p12 dimers. In CPP32, 3 residues are inserted into the loop between strand a and helix 1 (denoted loop 1), and 10 residues into the loop between helix 5 and strand f (denoted loop 3). In ICE, the loop between strand c and helix 3 (denoted loop 2) is 6 residues longer.


Fig. 3. Stereo plot of the superposition of ICE and CPP32 based on the C-alpha atoms from one p17/p12 dimer. C-alpha atoms from the CPP32 structure are indicated by black dots. All residue numbers refer to the CPP32 structure, except Arg-391. The numbers indicate regions where deletions/insertions occur.
[View Larger Version of this Image (34K GIF file)]


In CPP32, there is also a single residue deletion within strand f. In ICE, this residue (Arg-391) forms a beta -bulge that is absent in CPP32. From the sequence alignment shown in Fig. 4, it becomes evident that these insertions and deletions are conserved in many other CED3/ICE-like proteases. Particularly the insertion into loop 3, the deletions of the residues in loop 2, and the absence of a beta -bulge are specific for the CED3-like subclass. The insertion into loop 1 is also found in many other proteases from the CED3-like subclass, but not in CED3 itself. The conservation of this deletion/insertion pattern implies that the other members of the CED3-like subclass could have structures that are more similar to CPP32 than to ICE. Since most of these differences appear around the active site, they would be expected to affect the specificities of the ICE- and CED3-like subclasses.


Fig. 4. Multiple partial sequence alignment of CED3/ICE-like proteases. All proteins are human except those indicated by the number sign and the asterisk, which come from mouse and C. elegans, respectively. The active-site residues are boxed. Insertions that are specific for the ICE and CED3 subclasses are highlighted in black and gray. Loops 1-3 refer to the loops between beta -strands and alpha -helices a/1, c/3, and f/5, respectively. The black bars at the bottom indicate the subunits in CPP32.
[View Larger Version of this Image (30K GIF file)]


Inhibitor Binding

The inhibitor Ac-DVAD-fmk binds in a narrow cleft across the C-terminal end of the central beta -sheet. All atoms are well defined in the electron density (Fig. 5). The active-site cysteine (Cys-163) resides on the elongation of strand d that makes a sharp 90° turn at the end of the beta -sheet (Fig. 1). The N terminus of the inhibitor binds between the N terminus of helix 4 and the C terminus of helix 5. As in many other proteases that are totally unrelated to CPP32, the inhibitor is recognized in a beta -sheet conformation (40). The main chain of the inhibitor is aligned antiparallel with residues 205-209, and the polar main chain atoms from P1, P3, and the acetyl protection group (denoted P5) form a beta -sheet-like hydrogen-bonding network (Table IV). The inhibitor is irreversibly bound through a thioether bond to the side chain of Cys-163 (Fig. 6A). The side chain of the inhibitor P1 Asp points into a deep pocket, forming salt bridges with Arg-64 and Arg-207 and a hydrogen bond with Gln-161. The binding of a small acidic residue in S1 is supported by the strong positive electrostatic potential exerted by the basic residues nearby (Figs. 6A and 7).


Fig. 5. Stereo plot of the electron density in the region of the bound inhibitor. The inhibitor is shown as a ball-and-stick model. The sigma A-weighted (Fo - Fc)-omit map was contoured at 2.5sigma . Residues 53-66, 119-124, 161-169, 202-210, and 248-260 from the protein are shown as a C-alpha model. Main chain breaks are marked by black dots.
[View Larger Version of this Image (22K GIF file)]


Table IV.

Polar interactions between CPP32 and Ac-DVAD-fmk


Binding site Atom in Ac-DVAD-fmk Atom in CPP32 Distance

Å
P1 Asp-993 O-delta 1 Arg-64 N-epsilon 2.8
Asp-993 O-delta 1 Arg-64 N-eta 2 3.3
Asp-993 O-delta 1 Arg-207 N-eta 1 2.9
Asp-993 O-delta 1 Arg-207 N-epsilon 3.1
Asp-993 O-delta 2 Arg-64 N-eta 2 2.8
Asp-993 O-delta 2 Gln-161 N-epsilon 2 3.0
Asp-993 O Gly-122 N 3.0
Asp-993 N Ser-205 O 2.8
P2
P3 Val-991 N Arg-207 O 2.7
Val-991 O Arg-207 N 2.7
P4 Asp-990 N Pho-250 O 3.4
Asp-990 O-delta 2 Trp-214 N-epsilon 1 3.1
Asp-990 O-delta 2 Asn-208-N-delta 2 3.4
Asp-990 O-delta 1 Phe-250 N 2.7
P5 Ace-989 O a Ser-209 N 3.1
Ace-989 O  Ser-209 O-gamma 2.8

a Ace, acetyl group.


Fig. 6. A, hydrogen bonds and salt bridges in the CPP32-Ac-DVAD-fmk complex. The inhibitor is covalently linked to the active-site Cys-163 via a thioether bond. The inhibitor is shown by thick lines. Hydrogen bonds are represented as dashed lines. B, binding modes of aldehyde (23, 24) and chloro/fluoromethyl ketone (c/fmk) (Ref. 25 and this work) inhibitors in ICE-like proteases. Both binding modes are different states of the tetrahedral intermediate.
[View Larger Version of this Image (22K GIF file)]



Fig. 7. Molecular surface of the CPP32 tetramer generated by GRASP (45). The molecule is seen parallel to the 2-fold axis. The surface is colored according to its electrostatic potential. Red and blue areas represent negative and positive charge density, respectively. Two Ac-DVAD-fmk molecules (colored according to atom type) bind to the tetramer. The inhibitor residues and the central cavity discussed under "Results and Discussion" are labeled.
[View Larger Version of this Image (111K GIF file)]


Fig. 8 shows a superposition of the ICE inhibitor Ac-YVAD-aldehyde with the CPP32 inhibitor Ac-DVAD-fmk. Both inhibitors differ at P4 and the fmk/aldehyde. Although the residue at P1 is thought to be the most rigid, there is some flexibility. The different conformations of the aspartic acid at P1 are due to the different conformations of the P1 carbonyl. In contrast to the structure of CPP32 in complex with Ac-DEVD-aldehyde (23), we can clearly identify the carbonyl oxygen pointing into the oxyanion hole and forming a hydrogen bond with the Gly-122 nitrogen. A similar interaction is observed in the crystal structure of ICE in complex with Ac-YVAD chloromethyl ketone (24). In the ICE-Ac-YVAD-aldehyde structure (25), the P1 carbonyl forms a hydrogen bond with the active-site histidine rather than pointing into the oxyanion hole. Rotonda et al. (23) proposed a similar interaction in the CPP32-Ac-DEVD-aldehyde structure. From the set of four structures of CED3/ICE-like protease-inhibitor complexes that are now available, we conclude that in the case of ketone inhibitors, the carbonyl interacts with the amide proton in the oxyanion hole. These results are in agreement with early structural studies on papain-chloromethyl ketone inhibitor complexes (41). Aldehyde inhibitors form a thiohemiacetal with the active-site thiol group. During the reaction of these inhibitors, the P1 carbonyl changes its hybridization from sp2 toward sp3. This shift involves a 90° rotation around the C-alpha -C bond (Fig. 8). Instead of interacting with the oxyanion hole as in a serine protease-aldehyde inhibitor complex (43), the thiohemiacetal hydroxyl group forms a hydrogen bond with the imidazole side chain of the active-site histidine. The CED3/ICE-like protease-aldehyde and the CED3/ICE-like protease-ketone complexes seem to represent different states of the same tetrahedral intermediate illustrated in Fig. 6B. In the case of aldehyde inhibitors, the oxyanion is substituted by a hydrogen, and in the case of ketone inhibitors, the active-site histidine does not activate the water molecule that normally attacks the carbonyl carbon. Indeed, CED3/ICE-like proteases seem to have a catalytic Cys-His dyad rather than the classical (Cys/Ser)-His-(Asn/Asp) triad (23-25).


Fig. 8. Stereo plot of a superposition of Ac-YVAD-aldehyde from the ICE structure onto Ac-DVAD-fmk from the CPP32 structure based on the C-alpha atoms of P1-P4. The atom types of the CPP32 inhibitor are indicated; carbon, nitrogen, and oxygen atoms are represented by big black, big gray, and small balls, respectively.
[View Larger Version of this Image (12K GIF file)]


Residues 248-259 from the loop between helix 5 and strand f create a flap that constricts the active-site pocket. The methyl side chain of Ala (P2) is pointing into a shallow depression that is created by the side chains of Tyr-204, Trp-206, and Phe-256 from the flap. Val (P3) is recognized only by its main chain interactions with the protease. There are no specific side chain interactions that discriminate between different residues at this site.

The P4 Asp side chain is buried in a narrow pocket. This pocket is rather hydrophilic and can accommodate small acidic side chains. The aspartic acid side chain forms hydrogen bonds with the side chains of Asn-208 and Trp-214 and with the main chain of Phe-250 from the flap. CPP32 favors binding of small acidic residues at P4 and rejects large aromatic residues. The differences in selectivity between ICE and CPP32 can be attributed to the size of the S4 pocket. In CPP32, the flap constricts the S4 pocket. This effect is supported by the substitution of Val-348 in ICE with Trp-214 in CPP32. The large tryptophan side chain prevents binding of a residue with a bulky aromatic side chain at P4.

The Ac-DVAD-fmk inhibitor carries an acetyl protection group at the N terminus. Since an acetyl group resembles a glycine lacking the amino group, it can be considered as a P5 residue. The bond between Asp (P4) and the acetyl group is trans, like a normal peptide bond, but in the ICE structure, the corresponding bond adopts a cis conformation (25). Whether this difference is real is difficult to state with confidence because, at 2.3-Å resolution, the distinction between an oxygen and a methyl group is dubious. In CPP32, the acetyl oxygen (P5) participates in hydrogen bonds with Ser-209. In ICE, this residue is substituted with Pro-343, which is unable to form similar hydrogen bonds with the protection group. It is therefore likely that the conformational differences described above are real.

Considering all deletions/insertions occurring in the ICE- and CED3-like subclasses discussed above, only the long insertion into loop 3 creating the flap interacts with the small molecular mass tetrapeptide inhibitor. Nevertheless, the deletions/insertions into loops 1 and 2 are well conserved throughout the members of the subclass, indicating that they have a certain function. Since these loops do not interact with P1-P5, they might have a function in the recognition of larger substrates or inhibitors. The 38-kDa cowpox virus serpin CrmA, for example, inhibits ICE, but has almost no effect on CPP32 (8).

Quaternary Structure

The structure of CPP32 contains two copies of the p17/p12 heterodimer. The 2-fold symmetry axis relating the two copies intersects the central beta -sheet between Val-266 and Val-266# and is oriented perpendicular to strand f. The interface between the two dimers covers an area of 2000 Å2. ICE is also a tetramer in the active form. Structural and mutagenesis data suggest that the integrity of the dimer/dimer interface is indispensable for ICE proteolytic activity (25). The CPP32 dimer/dimer interface contains four hydrogen bonds formed between main chain atoms from strands f and f# and between the C terminus of p17 and the N terminus of p12#, respectively (Fig. 9). Residues from helixes 5 and 5# make side chain interactions across the interface. In particular, Glu-231, His-234, Arg-238, and Glu-272 create a network of salt bridges at the bottom of the interface (data not shown). On the opposite side of the central beta -sheet, there is a deep cavity with dimensions of ~17 × 7 × 11 Å3 (Fig. 7). This cavity encompasses the 2-fold axis. The bottom of the cavity is hydrophobic, but the residues along the walls are hydrophilic. The cavity is filled with well ordered water molecules.


Fig. 9. Stereo plot of the main chain in ICE (thin lines) and CPP32 (thick lines) seen parallel to the 2-fold axis that relates the two p17/p12 heterodimers. The four hydrogen bonds at the interface are shown as dashed lines. Residues 326-332, 387-394, 326#-332#, and 387#-394# from ICE and residues 192-198, 263-269, 1192-1198, and 1263-1269 from CPP32 belong to beta -strands e, f, e#, and f#, respectively. The structures were superimposed based on all residues from the first p17/p12 dimer (denoted e and f). In ICE, Arg-391 creates a beta -bulge (indicated by a black dot) and perturbs the regular hydrogen bonding pattern observed in CPP32.
[View Larger Version of this Image (22K GIF file)]


The topology of the interface in ICE differs from that in CPP32. None of the side chains that form hydrogen bonds across the interface are conserved, and the hydrogen bonding pattern between main chain atoms is different (Fig. 9). These differences are mainly caused by the insertion in ICE of a single residue (Arg-391) into strand f. In ICE, this residue forms a beta -bulge, which disturbs the regular hydrogen bonding pattern of the antiparallel beta -strands f and f# and affects the quaternary structure of the enzyme. Due to this insertion and the changes at the interface, the respective relative orientation of the p17/p12 dimer is different in ICE and CPP32. A superposition of the whole tetramer based on the residues from a single dimer reveals that the second dimer of CPP32 is rotated 13° relative to the second dimer of ICE (Fig. 10). The rotation axis is located in the plane of the central beta -sheet and runs perpendicular to the 2-fold axis. The rotation affects the two active sites of the tetramer. In CPP32, the rotation angle between the active sites is 13° smaller than in ICE. Another consequence of the different interface topologies is the shrinkage of the cavity between the p17/p12 dimers. In ICE, this cavity possesses roughly the same depth as in CPP32 (11 Å), but it is only 9 × 5 Å2 wide. Since the insertion of one additional residue into strand f is conserved throughout the whole ICE-like subclass (Fig. 4), it can be anticipated that the different dimer orientations are conserved in the CED3- and ICE-like subclasses as well. This hypothesis is supported by the observation that several residues at the interface that form side chain-specific hydrogen bonds are also conserved. The different angles between the heterodimers in the ICE- and CED3-like subclasses affect the relative orientations of the two active sites in the tetramer. This might be an important feature in substrate recognition. ICE and CPP32 are very likely involved in a reaction cascade that includes several ICE-like proteases (44). A detailed interaction scheme of this cascade still needs to be elucidated. The individual members of this cascade are activated by proteolytic cleavage of the proenzyme between the two subunits of the heterodimer. Whether the tetramer is formed before the protein is activated or not is still an open question. If the CED3/ICE proteases are activated by cleavage of an inactive tetramer at two sites simultaneously, the angle between the active sites is an important feature that determines the selectivity of the activating protease. No structure of a proenzyme of the CED3/ICE protease family is known yet. Therefore, it is presently impossible to say whether the relative orientations of the two active sites in ICE or CPP32 correspond to the orientations of the cleavage sites.


Fig. 10. Schematic superposition of the ICE and CPP32 tetramers. The two CPP32 dimers are represented by dark and light gray cylinders. The ICE tetramer is not shaded. Thick arrows on the ends of the cylinders indicate the active sites. When the superposition is made based on the residues from the first p17/p12 dimers, the second dimers differ by a rigid-body rotation of 13°. The rotation axis (dotted arrow) is oriented perpendicular to the 2-fold axis.
[View Larger Version of this Image (76K GIF file)]



FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and structure factors (code 1CP3) have been deposited in the Protein Data Bank, Brookhaven National Laboratory, Upton, NY.


§   Contributed equally to this work.
par    To whom correspondence should be addressed. Tel.: 41-61-696-6328; Fax: 41-61-696-9301; E-mail: gruetter{at}fmi.ch.
1   The abbreviations used are: ICE, interleukin-1beta -converting enzyme; serpin, serine protease inhibitor; Ac-YVAD-aldehyde, acetyl-Tyr-Val-Ala-Asp-aldehyde; Ac-DEVD-aldehyde, acetyl-Asp-Glu-Val-Asp-aldehyde; Ac-DVAD-fmk, acetyl-Asp-Val-Ala-Asp fluoromethyl ketone; Ac-DEVD-amc, acetyl-Asp-Glu-Val-Asp aminomethylcoumarin; OBut, t-butoxy; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.
2   R-factor (Rf) and Rsym are defined as follows: Rsym = Sigma hklSigma i|Ihkl,i - < Ihkl> |/Sigma hklSigma i|Ihkl,i|; Rf = Sigma hkl|Fobs(hkl)- k|Fcalc(hkl)|/Sigma hkl|Fobs(hkl)|.

Acknowledgments

We thank Gary Wilson for CPP32 pilot purification and Lisa Trout for administrative assistance.


REFERENCES

  1. Yuan, J. Y., Shaham, S., Ledoux, S., Ellis, H. M., and Horvitz, H. R. (1993) Cell 75, 641-652 [Medline] [Order article via Infotrieve]
  2. Xue, D., Shaham, S., and Horvitz, H. R. (1996) Genes Dev. 10, 1073-1083 [Abstract]
  3. Gagliardini, V., Fernandez, P.-A., Lee, R. K. K., Drexier, H. C. A., Rotello, R. J., Fishman, M. C., and Yuan, J. (1994) Science 263, 826-828 [Medline] [Order article via Infotrieve]
  4. Steller, H. (1995) Science 267, 1445-1449 [Medline] [Order article via Infotrieve]
  5. Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. (1994) J. Biol. Chem. 269, 30761-30764 [Abstract/Free Full Text]
  6. Horvitz, H. R., Shaham, S., and Hengartner, M. O. (1994) Cold Spring Harbor Symp. Quant. Biol. 111, 377-385
  7. Thornberry, N. A., Bull, H. D., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Ellison, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J.-F., Egger, L. A., Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T.-T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) Nature 396, 768-774
  8. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, A. M., Smulson, M. E., Yamin, T.-T., Yu, V. L., and Miller, D. K. (1995) Nature 376, 37-43 [CrossRef][Medline] [Order article via Infotrieve]
  9. Ramage, P., Cheneval, D., Chvei, M., Graff, P., Hemming, R., Heng, R., Kocher, H. P., Mackenzie, A., Memmert, K., Revesz, L., and Wishart, W. (1995) J. Biol. Chem. 270, 9378-9383 [Abstract/Free Full Text]
  10. Boulakia, C. A., Chen, G., Ng, F. W. H., Teodoro, J. G., Branton, P. E., Nicholson, D. W., Poirier, G. G., and Shore, G. C. (1996) Oncogene 12, 529-535 [Medline] [Order article via Infotrieve]
  11. Chinnaiyan, A. M., Orth, K., O'Rourke, K., Duan, H., Poirier, G. G., and Dixit, V. M. (1996) J. Biol. Chem. 271, 4573-4576 [Abstract/Free Full Text]
  12. Armstrong, R. C., Aja, T., Xiang, J., Gaur, S., Krebs, J. F., Hoang, K., Bai, X., Korsmeyer, S. J., Karanewsky, D. S., Fritz, L. C., and Tomaselli, K. J. (1996) J. Biol. Chem. 271, 16850-16855 [Abstract/Free Full Text]
  13. Slee, E. A., Zhu, H., Chow, S. C., MacFarlane, M., Nicholson, D. W., and Cohen, G. M. (1996) Biochem. J. 315, 21-24 [Medline] [Order article via Infotrieve]
  14. Fernandes-Alnemri, T., Armstrong, R. C., Krebs, J. F., Srinivasula, S. M., Wang, L., Bullrich, F., Fritz, L. C., Trapani, J. A., Tomaselli, K. J., Litwack, G., and Alnemri, E. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7464-7469 [Abstract/Free Full Text]
  15. Liu, X., Kim, C. N., Pohl, J., and Wang, X. (1996) J. Biol. Chem. 271, 13371-13376 [Abstract/Free Full Text]
  16. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) Cell 81, 801-809 [Medline] [Order article via Infotrieve]
  17. Casciola-Rosen, L., Nicholson, D. W., Chong, K. R., Thornberry, N. A., Miller, D. K., and Rosen, A. (1996) J. Exp. Med. 183, 1957-1964 [Abstract]
  18. Goldberg, Y. P., Nicholson, D. W., Rasper, D. M., Kalchman, M. A., Koide, H. B., Graham, R. K., Bromm, M., Kazemi-Esfarjani, P., Thornberry, N. A., Vaillancourt, J. P., and Hayden, M. R. (1996) Nat. Genet. 13, 442-449 [Medline] [Order article via Infotrieve]
  19. Milligan, C. E., Prevette, D., Yaginuma, H., Homma, S., Cardwell, C., Fritz, L. C., Tomaselli, K. J., Oppenheim, R. W., and Schwartz, L. M. (1995) Neuron 15, 385-393 [Medline] [Order article via Infotrieve]
  20. Rabizabeh, S., La Count, D. J., Freisen, P. D., and Bredesen, D. E. (1993) J. Neurochem. 61, 2318-2321 [Medline] [Order article via Infotrieve]
  21. Gu, Y., Sarnecki, C., Aldape, R. A., Livingston, D. J., and Su, M. S.-S. (1995) J. Biol. Chem. 270, 18715-18718 [Abstract/Free Full Text]
  22. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347 [CrossRef][Medline] [Order article via Infotrieve]
  23. Rotonda, J., Nicholson, D. W., Fazil, K. M., Gallant, M., Gareau, Y., Labelle, M., Peterson, E. P., Rapser, D. M., Ruel, R., Vaillancourt, J. P., Thornberry, N. A., and Becker, J. W. (1996) Nat. Struct. Biol. 3, 619-625 [Medline] [Order article via Infotrieve]
  24. Walker, N. P. C., Talanian, R. V., Brady, K. D., Dang, L, C., Bum, N. J., Ferenz, C. R., Franklin, S., Ghayur, M., Hackett, M. C., Hammill, L. C., Herzog, L., Hugunin, M., Houy, W., Mankovich, J. A., McGuiness, L., Orlewicz, E., Paskind, M., Pratt, C. A., Reis, P., Summani, A., Terranova, M., Welch, J. P., Xiong, L., Moller, A., Tracey, D. E., Kamen, R., and Wong, W. W. (1994) Cell 78, 343-352 [Medline] [Order article via Infotrieve]
  25. Wilson, K. P., Black, J. F., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A., Murcko, M. A., Chambers, S. P., Aldape, R. A., Raybuck, S. A., and Livingston, D. J. (1994) Nature 370, 270-275 [CrossRef][Medline] [Order article via Infotrieve]
  26. Revesz, L., Briswalter, C., Heng, R., Leutwiler, A., Mueller, R., and Waethrich, H.-J. (1994) Tetrahedron Lett. 35, 9693-9696 [CrossRef]
  27. Börnsen, O. K., Schär, M., and Widmer, H. M. (1990) Chimia 44, 412-416
  28. Schägger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379 [Medline] [Order article via Infotrieve]
  29. Neuhoff, V., Stamm, R., and Eibl, H. (1985) Electrophoresis 6, 427-448
  30. McPherson, A. (1989) in Preparation and Analysis of Protein Crystals (McPherson, A., ed), pp. 94-97, Krieger Publishing Co., Malabar, FL
  31. Collaborative Computational Project No. 4 (1994) Acta Crystallogr. Sect. D 50, 760-763 [CrossRef][Medline] [Order article via Infotrieve]
  32. Kabsch, W. (1993) J. Appl. Crystallogr. 25, 795-800 [CrossRef]
  33. Kabsch, W. (1988) J. Appl. Crystallogr. 21, 67-71 [CrossRef]
  34. Nazava, J. (1994) Acta Crystallogr. Sect. D 50, 157-163 [CrossRef]
  35. Brünger, A. T., Kuriyan, J., and Karplus, M. (1987) Science 235, 458-460
  36. Jones, T. A., Zou, J.-Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sect. A 47, 110-119 [CrossRef][Medline] [Order article via Infotrieve]
  37. Zulauf, M., and D'Arcy, A. (1992) J. Crystal Growth 122, 102-106 [CrossRef]
  38. Wang, X., Zelenski, N. G., Yang, J., Sakai, J., Brown, M. S., and Goldstein, J. L. (1996) EMBO J. 15, 1012-1020 [Abstract]
  39. Darmon, A. J., Nicholson, D. W., and Bleackley, R. C. (1995) Nature 377, 446-448 [CrossRef][Medline] [Order article via Infotrieve]
  40. Bode, W., and Huber, R. (1992) Eur. J. Biochem. 204, 433-451 [Abstract]
  41. Drenth, J., Kalk, K. H., and Swen, H. M. (1976) Biochemistry 15, 3731-3738 [Medline] [Order article via Infotrieve]
  42. James, M. N. G., Sielecki, A. R., Brayer, G. D., Delbaere, L. T. J., and Bauer, A. (1980) J. Mol. Biol. 144, 43-51 [Medline] [Order article via Infotrieve]
  43. Kumar, S., and Harvey, N. L. (1995) FEBS Lett. 375, 169-173 [CrossRef][Medline] [Order article via Infotrieve]
  44. Kraulis, P. (1991) J. Appl. Crystallogr. 24, 946-950 [CrossRef]
  45. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins Struct. Funct. Genet. 11, 281-296 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.